Search

everythinglearnresearchcommunity

for

Search:↓

JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.

Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

JAK inhibitors show promise for treating alopecia areata but have serious side effects.

Secukinumab and acitretin together may quickly and effectively treat severe generalized pustular psoriasis.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Injectable platelet-rich fibrin can safely and effectively treat melasma.

Infliximab successfully treated a severe hair loss case in Sri Lanka.

JAK inhibitors may help treat alopecia areata and promote hair regrowth.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.

Tofacitinib may help regrow hair in alopecia areata patients.

JAK inhibitors can help treat alopecia areata but have risks and high costs.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.